![James Ferguson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 3 M $ in data 31/08/2026
James J.
Ferguson is currently Chief Medical Officer at Mineralys Therapeutics, Inc. since 2026.
Former positions include Chief Medical Officer at Cadrenal Therapeutics, Inc. from 2025 to 2026, Chief Medical Officer at Matinas BioPharma Holdings, Inc. from 2019 to 2024, Head-Cardiovascular & Bone Therapeutic at Amgen, Inc. from 2016 to 2019, Vice President-Global Medical Affairs at AstraZeneca PLC from 2010 to 2016, VP-Global Medical, Surgical & Critical Care at The Medicines Co. from 2009 to 2010, Associate Director-Clinical Cardiology Research at Texas Heart Institute from 1987 to 2008, Director-Cardiology Fellowship Training Program at St. Luke's Episcopal Hospital, Associate Professor at Baylor College of Medicine, and Clinical Assistant Professor at The University of Texas Health Science Center at Houston.
Education includes undergraduate studies at Harvard University and a doctorate from the University of Pennsylvania Medical Center.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/08/2026 | 102.400 ( 0,13% ) | 3 M $ | 31/08/2026 | |
| 27/07/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 10/08/2026 |
| Società | Posizione | Fine |
|---|---|---|
| CADRENAL THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 31/07/2026 |
| MATINAS BIOPHARMA | Direttore Tecnico/Scientifico/R&S | 31/10/2024 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2019 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/08/2016 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01/05/2010 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Matinas BioPharma Holdings, Inc.
 Matinas BioPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Luke's Episcopal Hospital
 St. Luke's Episcopal Hospital Hospital/Nursing ManagementHealth Services Provides medical and health care services | Health Services |
Baylor College of Medicine
 Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Texas Heart Institute
 Texas Heart Institute Hospital/Nursing ManagementHealth Services Provides an avenue for exchange of ideas relating to the clinical and research activities | Health Services |
University of Pennsylvania Medical Center
 University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas Health Science Center at Houston
 The University of Texas Health Science Center at Houston Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mineralys Therapeutics, Inc.
 Mineralys Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines to target diseases | Health Technology |
Cadrenal Therapeutics, Inc.
 Cadrenal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapy with orphan drug indication | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
